WTF with Rhythm: How GeneType personalises disease prevention

Tylah Tully chats with Rhythm Biosciences (ASX:RHY) Director of Clinical and Scientific Affairs Dr Erika Spaeth, who explains the growing role of polygenic risk scores (PRS) in preventive healthcare.

Dr. Spaeth highlights Rhythm’s GeneType risk assessment, which predicts risk for nine diseases – six cancers (breast, ovarian, prostate, colorectal, pancreatic, and melanoma) and three cardiometabolic conditions.

She notes that with initiatives like Genomics Australia’s $50 million investment, PRS is expected to become an integral part of future screening programs, improving risk stratification and enabling earlier, more targeted interventions.

Watch the video for more.

This video was developed in collaboration with Rhythm Biosciences, a Stockhead client at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.